Ignite Creation Date:
2025-12-24 @ 3:06 PM
Ignite Modification Date:
2026-03-24 @ 4:24 PM
Study NCT ID:
NCT02146859
Status:
COMPLETED
Last Update Posted:
2018-03-27
First Post:
2014-05-16
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Sponsor:
Mahidol University
Organization:
Study Overview
Official Title:
Predictor of Residual Neuromuscular Blockade in Recovery Room After General Anesthesia
Status:
COMPLETED
Status Verified Date:
2018-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Background When general anesthesia was performed, neuromuscular blocking agents (NMBAs) are frequently used for facilitate tracheal intubation and keep patient still and relax during surgery. Unfortunately, residual neuromuscular blockade are important complication.
There are many factors that affect neuromuscular blockade and may prolong effect of NMBAs which we already know about that such as body temperature, drugs, some kind of diseases. However there are no recent studies that mention about other factors. The purpose of this study is to find out other factors that affect NMBAs effect to improve patient safety.
Methods The study is a prospective, non-randomized, blinded, observational study.
222 patients will be included in this study and will be performed general anesthesia. Anesthetic technique and agent which are used depend on regular staff. Information of patient will be collected are age, sex, weight, height, ASA classification, anesthetic technique, anesthetic and surgical time, amount of inhalation agent, amount of NMBAs, amount of opioids and reversal agents.
After anesthesia finish, patient will be brought to recovery room and Train Of Four watch® will be placed and record Train Of Four ratio by this research staff. Train Of Four ratio \< 0.9 will be defined as there is residual neuromuscular blockade in this patient.
All patients will be divided into 2 groups: residual blockade group(patient who have train of four \<0.9 after surgery) and no residual blockade group(patient who have train of four \>0.9). All factor of each group will be compared between. Statistical will be analyzed to find significant factor which affect neuromuscular blockade.
There are many factors that affect neuromuscular blockade and may prolong effect of NMBAs which we already know about that such as body temperature, drugs, some kind of diseases. However there are no recent studies that mention about other factors. The purpose of this study is to find out other factors that affect NMBAs effect to improve patient safety.
Methods The study is a prospective, non-randomized, blinded, observational study.
222 patients will be included in this study and will be performed general anesthesia. Anesthetic technique and agent which are used depend on regular staff. Information of patient will be collected are age, sex, weight, height, ASA classification, anesthetic technique, anesthetic and surgical time, amount of inhalation agent, amount of NMBAs, amount of opioids and reversal agents.
After anesthesia finish, patient will be brought to recovery room and Train Of Four watch® will be placed and record Train Of Four ratio by this research staff. Train Of Four ratio \< 0.9 will be defined as there is residual neuromuscular blockade in this patient.
All patients will be divided into 2 groups: residual blockade group(patient who have train of four \<0.9 after surgery) and no residual blockade group(patient who have train of four \>0.9). All factor of each group will be compared between. Statistical will be analyzed to find significant factor which affect neuromuscular blockade.
Detailed Description:
study about residual neuromuscular blockade
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: